Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data

Clicks: 27
ID: 328990
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #65 of 411 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 411 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Systemic treatments for psoriasis confer differential risk profiles for infections such as tuberculosis, meningitis, candidiasis and other fungal infections. However, real-world comparative data including IL-17 and 23 inhibitors remain limited. METHODS: We conducted a nationwide cohort study using data from British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) from 2007 to 2024. Adults with psoriasis receiving systemic treatments were included and followed from treatment initiation until treatment discontinuation, death, or last available follow-up data. Primary outcomes included tuberculosis, meningitis, candidiasis and other fungal infections. Incidence rates per 1000 person-years were calculated and incidence rate ratios (IRRs) were estimated using doubly robust interval-based Poisson regression model. Entropy balancing method was used to achieve covariate balance across treatment groups and multiple imputation was used to handle missing baseline data. RESULTS: A total of 40,930 treatment episodes from 18,635 patients contributing 118,018 person-years of follow-up were included in this analysis. During the follow-up, 22 tuberculosis cases, 29 meningitis cases, and 888 fungal infection cases including 450 candidiasis were reported. The overall incidence rates were 0.19 (95% CI 0.12 to 0.29) for tuberculosis, 0.25 (95% CI 0.16 to 0.35) for meningitis, and 7.53 (95% CI 7.05 to 8.05) for fungal infections per 1000 person-years. Most tuberculosis and meningitis cases were associated with TNF-α inhibitors, particularly adalimumab. Meningitis was predominantly viral and tuberculosis was largely pulmonary. 30-day mortality was observed in fewer than 5 cases in meningitis. IL-17 inhibitors alone exhibited increased risk of candidiasis compared to all other systemic treatment groups with IRRs ranging from 2.67 (95% CI 1.33 to 5.36) versus apremilast to 4.65 (95% CI 3.46 to 6.24) versus IL-12/23 inhibitor. Individual IL-17 inhibitors did not exhibit significant differences in the candidiasis risk. With fungal infections other than candidiasis, no statistically significant differences were observed between treatment groups. CONCLUSIONS: In this large cohort study, tuberculosis and meningitis were rare and longer-term follow-up is required to further characterise the risk with newer treatments. Candidiasis and fungal infections were more common with increased risks among patients receiving IL-17 inhibitors.
Reference Key
openalex_W7213365611 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Heber Rew Bright, Catherine H Smith, Philip Laws, Nick J Reynolds, Duc Binh Phan, Mark Lunt, Richard B. Warren, Zenas Z N Yiu
Are you one of these authors? Claim your profile
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag397
URL
https://doi.org/10.1093/bjd/ljag397
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.